Vice President Vance Rebuts Trump Stock Claims Amid Scrutiny
Vice President JD Vance publicly pushed back on questions about President Trump's stock trading, arguing that the bil...
When To Go Active In The Market
Knowing when to switch from passive to active strategies can boost returns. This guide outlines practical signals, costs, and risk considerations.
27,240 articlesAfter Venezuela Iran, Cuba? Markets Brace for Policy Shift
Investors weigh whether the next policy move could target Cuba after Venezuela and Iran, a shift that could ripple th...
Space Stocks Jump as SpaceMobile Jumps, Rocket Lab Climbs
Three leading space names moved higher in a risk-on trading session, with AST SpaceMobile, Rocket Lab and Planet Labs...
VYM, SCHD, SPHD Generate Steady Income Across 690 Stocks
Three dividend-focused ETFs—VYM, SCHD and SPHD—could deliver roughly $7,300 per year from about 690 underlying stocks...
QLAC Strategy That Lets a 70-Year-Old Defer RMDs
A practical look at how a Qualified Longevity Annuity Contract can shrink current RMDs for a high‑net‑worth retiree a...
BP Ousts Chairman Months Into Tenure, Governance Probe
BP unexpectedly removes its chairman just months after his appointment, citing governance standards and conduct conce...
U.S. Government Just Billion: What It Means for Investors
The U.S. government is backing quantum startups with billions. Here’s how that move could affect stock selection, ris...
Ethereum Price Prediction: Falls Below 2K, What’s Next
ETH dips below the $2,000 mark as global risk-off sentiment intensifies. Analysts warn the pullback could extend unle...
Bomb: Employer Stock Inside 401(k) Could Cost Dearly
A retiring executive with a $4+ million 401K and a heavy concentration in employer stock faces a potential tax trap. ...
Prediction: Royal Caribbean Still Has Room to Run Ahead
Royal Caribbean Cruises posted stronger-than-expected Q1 results, boosting its 2026 EPS outlook as demand for cruises...
Prediction: This AI Inference Stock Is Set to Soar
A bold investment thesis hinges on the AI inference niche. After June 3, the market could reward execution as much as...
Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status